Search Results
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
that the series is on track to deliver a late lead which meets the dose criteria for prophylaxis, i.e. a single dose <500mg for t>MIC for 7d (minimum) or a single dose <500mg for t>MIC for 28d (ideal). 3. Addressing the hERG inhibition
More news about: GHIT Fund
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.
Apr 21, 2026, 13:38 ET As Fluoride Debate Grips the Nation, Americans Turn to Whole-House Fluoride Filters for Answers
lower IQ scores.The science is contested. A November 2025 study in Science Advances found children exposed to fluoride at the recommended 0.7 mg/L level performed better on cognitive tests than unexposed peers. Meanwhile, a March 2026 CareQuest Institute analysis warned that fluoridation bans
More news about: SoftPro Water Systems
Apr 21, 2026, 10:32 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
June 2 in Chicago. The oral presentation will feature results from the Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in myelofibrosis.Presentation Details:Title: Selinexor plus ruxolitinib
More news about: Karyopharm Therapeutics Inc.
Apr 21, 2026, 10:01 ET EMI Shielding Market worth $10.90 billion by 2032 - Exclusive Report by MarketsandMarkets™
include PARKER HANNIFIN CORP (US), PPG Industries, Inc. (US), 3M (US), Hankel AG & CO KGAA (Germany), Qnity Electronics Inc (US), Leader Tech Inc (US), MG Chemicals (Canada), Nolato AB (Sweden), Tech Etch Inc (US), and RTP Company (US), among others.Get 10% Free Customization on this Report:
More news about: MarketsandMarkets
Apr 21, 2026, 08:30 ET Lasix® ONYU Now Available from Walmart Specialty Pharmacy for Home Delivery
The pharmaceutical component of Lasix ONYU is a novel, high-concentration formulation of the diuretic furosemide, at 30 mg/mL. It comes in a pre-filled glass cartridge containing 80 mg of furosemide in 2.67 mL. The Lasix ONYU Infusor consists of two main parts: the Reusable Unit and the Disposable Unit.
More news about: SQ Innovation
Apr 21, 2026, 07:00 ET Pharmactive Launches Kyoh® for Hair Growth Support
hair care, delivering natural, botanical-origin support through a rigorously defined composition." The company recommends a 300 mg daily intake at the beginning, followed by 100 mg for maintenance.Pharmactive will introduce Kyoh® and other branded ingredients, including
More news about: Pharmactive Biotech Products, S.L.U.
Apr 20, 2026, 22:04 ET Twofold Launches Revolutionary THC Spirits Alternative on 4/20, Introducing a New Standard for Modern Drinking
ready-to-drink formats, Twofold is presented in a 750ml spirits bottle and designed for structured cocktail use. Each expression delivers a precise 2mg dose per 1.5oz pour, enabling predictable, repeatable consumption that aligns with standard bar service and pacing.The launch comes at a time
More news about: Twofold
Apr 20, 2026, 09:30 ET Myasthenia Gravis Foundation of America Launches MGFA Food Support Program to Advance Nutrition Access and Health Equity for Individuals with Myasthenia Gravis
Food Support Program, MG families will:benefit from tangible, immediate support at mealtimes,advance health equity by addressing a key social determinant of overall health, and,be part of an important MG community program that lowers MG symptom impact and stress
More news about: Myasthenia Gravis Foundation of America, Inc.
Apr 20, 2026, 08:32 ET ATACH Releases Comprehensive Report on the Future of Hemp
covers:What Congress changed — P.L. 119-37 replaces the delta-9-only standard with a total THC framework, imposes a 0.4 mg per-container cap on finished products, and excludes synthetic and chemically converted cannabinoids from the definition of hemp and hemp cannabinoid
More news about: American Trade Association for Cannabis and Hemp
Apr 20, 2026, 08:05 ET Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Now Preferred Under Cigna Healthcare Commercial Plans
www.fda.gov/medwatch. IMULDOSA is supplied as single-dose prefilled syringes for subcutaneous use in 45 mg/0.5 mL and 90 mg/mL strengths or as a single-dose vial for intravenous infusion in 130 mg/26 mL (5 mg/mL) strength.For more information, please see the
More news about: Accord BioPharma
Apr 20, 2026, 08:00 ET CMP Pharma Announces Availability of a New Alcohol-Free Reformulation of Norliqva® (Amlodipine) Oral Solution
with a maximum of 10 mg orally once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg orally once daily. Pediatric starting dose: 2.5 mg to 5 mg orally once daily.Please click link for full Important Safety Information and full Prescribing
More news about: CMP Pharma, Inc.
Apr 20, 2026, 07:30 ET 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
https://doi.org/10.1111/ddg.14689National Alopecia Areata FoundationAlhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs. Clin Cosmet Investig Dermatol. 2023;16:803-820
More news about: Nektar Therapeutics
Apr 20, 2026, 07:00 ET Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
100 mm³, mice were randomized into four groups: vehicle control; Quar Oze alone (25 μg/mouse, IV, every three days); alectinib alone (0.5 mg/kg for sensitive or 15 mg/kg for resistant, oral, daily); and Quar Oze plus alectinib at the same doses. In the sensitive model, tumors in the alectinib-treated group
More news about: Genprex, Inc.
Apr 20, 2026, 06:45 ET U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated
More news about: Astellas Pharma Inc.
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
pharmacokinetics (PK) / Pharmacodynamics (PD) profile compared to BL-B01D1 in the FaDu CDX model:Greater potency: At 5 mg/kg, exposure (AUC) was comparable between the two ADCs, but tumor regression in the CS5007 group was significantly greater than that in the BL-B01D1 group
More news about: CStone Pharmaceuticals
Apr 19, 2026, 18:00 ET Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
platformTumor regressions observed across various cancer models at low single‑digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC)Phase 1 trials for HWK-007 and HWK-016 are
More news about: Whitehawk Therapeutics, Inc.
Apr 19, 2026, 13:19 ET Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
preventive treatment administered as one 30-minute IV infusion 4 times a year (every three months). The recommended dosage is 100 mg, and some patients may benefit from a dosage of 300 mg. Dosing should be based on the guidance in the Prescribing Information and Patient Information. VYEPTI (eptinezumab-jjmr)
More news about: H. Lundbeck A/S
Apr 18, 2026, 14:59 ET Best Home Saunas of 2026: 8 Brands Compared by Heat Type, Construction, Safety Data, and Warranty
0.5 mG (Vitatech)0.5 mG (Vitatech)
More news about: Sun Home Saunas
Apr 17, 2026, 22:38 ET 再鼎醫藥公布最新數據，顯示Zocilurtatug Pelitecan (Zoci) 在小細胞肺癌腦轉移患者中實現快速且顯著的顱內緩解，並在其他神經內分泌癌中展現出良好活性
Zoci，一款潛在同類首創的DLL3靶向抗體藥物偶聯物（ADC），在小細胞肺癌（SCLC）腦轉移患者中顯示出53.7%的確認顱內客觀緩解率（iORR）；在1.6mg/kg劑量下，確認的iORR為62.5%（10/16)，包括顱內腫瘤完全緩解的病例在肺外神經內分泌
More news about: 再鼎醫藥
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
PBMC-humanized 786-O kidney cancer xenograft models, ATG-106 induced tumor shrinkage in all treated mice, with complete remissions observed in the 0.1 mg/kg and 0.3 mg/kg groups. ATG-106 also induced tumor shrinkage and complete remission in PBMC-humanized OVCAR-3 ovarian cancer models. Notably, pro-inflammatory
More news about: Antengene Corporation Limited
Apr 17, 2026, 16:01 ET New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
available ROS1 TKIs have demonstrated activity in this heavily pre-treated population.Patients received at least 1 dose of zidesamtinib at 100 mg QD as of a data cut-off date of September 22, 2025. The population for this analysis was unique and heavily pre-treated:46 efficacy-evaluable
More news about: Nuvalent, Inc.
Apr 17, 2026, 15:29 ET 2026 Infrared Sauna Buyer's Guide: 8 Leading Brands Compared Across Heat, Safety, Warranty, and Design
0.5 mG (Vitatech)≤1.17 mG (Narda)Low EMF (3rd-party tested; specific mG not published)
More news about: Sun Home Saunas
Apr 17, 2026, 15:00 ET Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
Preliminary anti-tumor activity in heavily pretreated patients: Among patients with MSS colorectal cancer treated with IMT-009 monotherapy at 240 mg or higher, one confirmed partial response was observed, and one additional patient remained on treatment for 14 months with stable disease. In the combination
More news about: Immunitas Therapeutics, Inc.
Apr 17, 2026, 09:09 ET Theo's Gold-Backed Stablecoin Held Steady Through Global Disruption, Now Targets $1B in Deposits
in total value locked by the end of April and $1 billion by year-end.The infrastructure is institutional-grade. FundBridge Capital manages the MG999 Onchain Gold Fund that underpins thGOLD, while Libeara, a tokenisation platform incubated by Standard Chartered Ventures, handles the onchain architecture.
More news about: Theo